RAB35 (Ras-Related Protein Rab-35) is a member of the Rab GTPase family that plays critical roles in regulating actin dynamics, endocytic trafficking, and synaptic vesicle recycling at presynaptic terminals. Originally identified as a regulator of endocytic pathways, RAB35 has emerged as an important player in neuronal function, with growing evidence linking its dysfunction to neurodegenerative diseases including Parkinson's disease and Alzheimer's disease [1].
RAB35 operates as a molecular switch, cycling between an active GTP-bound state and an inactive GDP-bound state. Its unique feature among Rab GTPases is its ability to regulate both actin cytoskeleton dynamics and membrane trafficking simultaneously, making it essential for proper synaptic function [2].
| Gene Symbol | RAB35 |
| Full Name | Ras-Related Protein Rab-35 |
| Chromosome | 12q24.31 |
| NCBI Gene ID | 11020 |
| OMIM | 607352 |
| Ensembl ID | ENSG00000131721 |
| UniProt | Q8WVM8 |
| Protein Name | Ras-related protein Rab-35 |
| Associated Diseases | Parkinson's Disease, Encephalopathy, Synaptic dysfunction |
RAB35 is predominantly localized to presynaptic terminals where it plays a central role in synaptic vesicle endocytosis and recycling. Following neurotransmitter release, synaptic vesicles undergo endocytosis to be recycled for subsequent rounds of release. RAB35 directly regulates this process by controlling the formation and trafficking of synaptic vesicle precursors from the plasma membrane back to the synaptic vesicle pool [2:1].
The mechanism involves RAB35 interacting with several effector proteins:
RAB35 uniquely regulates both membrane trafficking and actin dynamics through its effector MICAL-1 (Mik-related Cleavage Site). This interaction is particularly important in neuronal growth cones and dendritic spines, where actin remodeling is essential for synaptic plasticity and neurite outgrowth [3].
Key functions include:
Beyond synaptic vesicle recycling, RAB35 regulates trafficking through the endosomal system. It controls the movement of cargo between early endosomes and later compartments, including recycling endosomes that return proteins to the plasma membrane [4].
RAB35 is highly expressed in the brain, particularly in:
Within neurons, RAB35 localizes to:
Growing evidence implicates RAB35 dysfunction in Parkinson's disease (PD). The gene is located near susceptibility loci identified in genome-wide association studies (GWAS), and RAB35 has been shown to interact with PD-related proteins including LRRK2 and GBA [5].
Mechanisms linking RAB35 to PD:
RAB35 may also play roles in Alzheimer's disease pathogenesis:
RAB35 represents a potential therapeutic target for neurodegenerative diseases. Strategies under investigation include:
| Effector | Function |
|---|---|
| MICAL-1 | Actin regulation |
| OCRL | Phosphoinositide metabolism |
| FYCO1 | Autophagosome/lysosome trafficking |
| SNX17 | Endosomal protein recycling |
| RABEP1 | Vesicle tethering |
RAB35 is located in a genomic region that has been associated with:
Rare variants in RAB35 have been associated with:
RAB35 in PD pathogenesis: More detailed mechanistic studies are needed to clarify how RAB35 dysfunction contributes to dopaminergic neuron loss. Current evidence is largely correlative, and causal relationships remain to be established through conditional knockout models and patient-derived neurons.
Effector selectivity: Developing effectors-specific modulators that target particular RAB35-effector interactions rather than RAB35 itself could provide safer therapeutic candidates with fewer off-target effects.
In vivo models: Creating and characterizing RAB35 knockout/knockin models, particularly in dopaminergic neurons, will be crucial for understanding its role in PD pathogenesis and testing therapeutic interventions.
Biomarkers: Identifying RAB35-related biomarkers for diagnosis and disease progression monitoring. This could include measuring RAB35 levels in cerebrospinal fluid or using PET ligands that detect RAB35-associated pathology.
Therapeutic delivery: Optimizing brain delivery of RAB35-targeting compounds across the blood-brain barrier remains a significant challenge. Novel delivery approaches such as intranasal administration or focused ultrasound-mediated delivery may be necessary.
Multiple lines of evidence support RAB35 as a relevant therapeutic target:
Genetic Evidence:
Cellular and Molecular Evidence:
Animal Model Evidence:
RAB35 joins a growing list of RAB GTPases implicated in neurodegenerative diseases:
| RAB GTPase | Primary Function | Disease Association |
|---|---|---|
| RAB35 | Synaptic vesicle recycling | PD, AD |
| RAB39B | Endolysosomal trafficking | PD, intellectual disability |
| RAB7 | Late endosomal/lysosomal trafficking | Charcot-Marie-Tooth disease |
| RAB3A/B | Neurotransmitter release | PD, schizophrenia |
| RAB11A | Synaptic plasticity | AD, ASD |
RAB35's unique dual role in actin regulation and membrane trafficking makes it distinct from other neuronal RAB GTPases and may provide opportunities for selective therapeutic modulation.